Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRAF V600K
i
Other names:
BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
673
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Related tests:
FoundationOne® CDx (110)
THXID® BRAF Kit (12)
FoundationOne® CDx (110)
THXID® BRAF Kit (12)
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
trametinib
Sensitive: A1 - Approval
trametinib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
binimetinib + encorafenib
Sensitive: A1 - Approval
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
vemurafenib + cobimetinib
Sensitive: A1 - Approval
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600K
Cutaneous Melanoma
BRAF V600K
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
trametinib + dabrafenib
Sensitive: A2 - Guideline
trametinib + dabrafenib
Sensitive
:
A2
BRAF V600K
Cutaneous Melanoma
BRAF V600K
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
BRAF V600K
Cutaneous Melanoma
BRAF V600K
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
BRAF V600K
Melanoma
BRAF V600K
Melanoma
dabrafenib
Sensitive: A2 - Guideline
dabrafenib
Sensitive
:
A2
dabrafenib
Sensitive: A2 - Guideline
dabrafenib
Sensitive
:
A2
BRAF V600K
Cutaneous Melanoma
BRAF V600K
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
binimetinib + encorafenib
Sensitive: A2 - Guideline
binimetinib + encorafenib
Sensitive
:
A2
BRAF V600K
Melanoma
BRAF V600K
Melanoma
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
BRAF V600K
Melanoma
BRAF V600K
Melanoma
encorafenib
Sensitive: B - Late Trials
encorafenib
Sensitive
:
B
encorafenib
Sensitive: B - Late Trials
encorafenib
Sensitive
:
B
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib + dabrafenib + PDR001
Sensitive: B - Late Trials
trametinib + dabrafenib + PDR001
Sensitive
:
B
trametinib + dabrafenib + PDR001
Sensitive: B - Late Trials
trametinib + dabrafenib + PDR001
Sensitive
:
B
BRAF V600K
Cutaneous Melanoma
BRAF V600K
Cutaneous Melanoma
trametinib
Sensitive: C1 - Off-label
trametinib
Sensitive
:
C1
trametinib
Sensitive: C1 - Off-label
trametinib
Sensitive
:
C1
BRAF V600K
Solid Tumor
BRAF V600K
Solid Tumor
binimetinib + encorafenib
Sensitive: C1 - Off-label
binimetinib + encorafenib
Sensitive
:
C1
binimetinib + encorafenib
Sensitive: C1 - Off-label
binimetinib + encorafenib
Sensitive
:
C1
BRAF V600K
Melanoma
BRAF V600K
Melanoma
pembrolizumab + trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
pembrolizumab + trametinib + dabrafenib
Sensitive
:
C2
pembrolizumab + trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
pembrolizumab + trametinib + dabrafenib
Sensitive
:
C2
BRAF V600K
Melanoma
BRAF V600K
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: C2 – Inclusion Criteria
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
C2
atezolizumab + vemurafenib + cobimetinib
Sensitive: C2 – Inclusion Criteria
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
C2
BRAF V600K
Solid Tumor
BRAF V600K
Solid Tumor
trametinib + dabrafenib + AT13387
Sensitive: C2 – Inclusion Criteria
trametinib + dabrafenib + AT13387
Sensitive
:
C2
trametinib + dabrafenib + AT13387
Sensitive: C2 – Inclusion Criteria
trametinib + dabrafenib + AT13387
Sensitive
:
C2
BRAF V600K
Melanoma
BRAF V600K
Melanoma
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
vemurafenib
Sensitive: C2 – Inclusion Criteria
vemurafenib
Sensitive
:
C2
BRAF V600K
Melanoma
BRAF V600K
Melanoma
BGB-283
Sensitive: C3 – Early Trials
BGB-283
Sensitive
:
C3
BGB-283
Sensitive: C3 – Early Trials
BGB-283
Sensitive
:
C3
BRAF V600K
Melanoma
BRAF V600K
Melanoma
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
nivolumab
Sensitive: C3 – Early Trials
nivolumab
Sensitive
:
C3
BRAF V600K
Melanoma
BRAF V600K
Melanoma
9-ING-41
Sensitive: C3 – Early Trials
9-ING-41
Sensitive
:
C3
9-ING-41
Sensitive: C3 – Early Trials
9-ING-41
Sensitive
:
C3
BRAF V600K
Melanoma
BRAF V600K
Melanoma
PD1 inhibitor + CTLA4 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor + CTLA4 inhibitor
Sensitive
:
C3
PD1 inhibitor + CTLA4 inhibitor
Sensitive: C3 – Early Trials
PD1 inhibitor + CTLA4 inhibitor
Sensitive
:
C3
BRAF V600K
Melanoma
BRAF V600K
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
Immunotherapy
Sensitive: C3 – Early Trials
Immunotherapy
Sensitive
:
C3
BRAF V600K
Melanoma
BRAF V600K
Melanoma
pembrolizumab + vemurafenib + cobimetinib
Sensitive: C3 – Early Trials
pembrolizumab + vemurafenib + cobimetinib
Sensitive
:
C3
pembrolizumab + vemurafenib + cobimetinib
Sensitive: C3 – Early Trials
pembrolizumab + vemurafenib + cobimetinib
Sensitive
:
C3
BRAF V600K
Melanoma
BRAF V600K
Melanoma
trametinib + dabrafenib + MCS110
Sensitive: C3 – Early Trials
trametinib + dabrafenib + MCS110
Sensitive
:
C3
trametinib + dabrafenib + MCS110
Sensitive: C3 – Early Trials
trametinib + dabrafenib + MCS110
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login